Clinical and economic assessment of CAR-T cell therapy for hematologic malignancies: systematization of global experience and prospects for the healthcare system of the Russian Federation

Background. Chimeric antigen receptor T-cell (CAR-T) therapy has changed the prognosis of patients with relapsed or refractory hematological malignancies but is among the most expensive oncology technologies: US list prices in 2025 were USD 462,000–594,000. Since April 2026, CAR-T therapy has been included in the Russian State Guarantees Programme, which makes the analysis of international economic evidence relevant. Objective: to systematize international experience in the economic evaluation of CAR-T therapy for hematological malignancies, to assess the comparability of its results, and to identify implications for the healthcare system of the Russian Federation. Material and methods. A narrative review of PubMed/MEDLINE, Scopus, Cochrane Library, eLibrary and CyberLeninka (January 2017 – June 2026) and of documents of regulatory and health technology assessment agencies was performed. For economic evaluations, country and perspective, comparator, willingness-to-pay threshold and results were compared; the Russian tariff was compared with international cost data converted at the official Bank of Russia exchange rate. A total of 50 sources were included. Results. In 47 economic evaluations, the incremental cost-effectiveness ratio (ICER) of CAR-T therapy ranged from USD 9,424 to 4,124,105 per quality-adjusted life year (QALY) in adults and from USD 20,784 to 243,177/QALY in children. The comparability of studies is limited by differences in comparators, survival extrapolation, discount rates, currencies and willingness-to-pay thresholds (from USD 37,700/QALY in China to USD 150,000/QALY in the USA). For the same indication (second-line axicabtagene ciloleucel in diffuse large B-cell lymphoma), US ICERs ranged from USD 66,381 to 142,327/QALY. A regression analysis of 45 studies found no association of cost-effectiveness with product, line of therapy or country. The Russian compulsory health insurance tariff of 7.03 million rubles (USD 88,200 at the Bank of Russia rate of April 6, 2026) is comparable with episode costs excluding the product in the UK (6.64 million rubles) and Italy (6.82 million rubles). Conclusion. Results of foreign economic evaluations of CAR-T therapy cannot be transferred to Russia without adaptation. Evidence-based reimbursement requires a national outcomes registry, data on actual costs of Russian centers with regular tariff revision, and methodological guidance for the evaluation of single-administration therapies.

Authors

Institutions

Publication Details

Journal
FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology
Published
2026-11-16
DOI
https://doi.org/10.17749/2070-4909/farmakoekonomika.2026.418
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical and economic assessment of CAR-T cell therapy for hematologic malignancies: systematization of global experience and prospects for the healthcare system of the Russian Federation

D. I. Islamgulova, M. E. Zaitsev, I. A. Prikhodko, N. O. Babkova et al.
1 links
FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology
CAR-T cell therapy research
article

Clinical and economic assessment of CAR-T cell therapy for hematologic malignancies: systematization of global experience and prospects for the healthcare system of the Russian Federation

D. I. Islamgulova, M. E. Zaitsev, I. A. Prikhodko, N. O. Babkova, O. A. Urubkova, Z. S. Busygina, R. Kh. Parchieva, M. A. Gilev, K. A. Tishchenko, N. S. Mamedova, N. O. Chernyakhovsky, E. A. Terenina, M. A. Zozulya, M. A. Temirkhanova, T. V. Sokolova, E. M. Vagapova
article en

Abstract

Background. Chimeric antigen receptor T-cell (CAR-T) therapy has changed the prognosis of patients with relapsed or refractory hematological malignancies but is among the most expensive oncology technologies: US list prices in 2025 were USD 462,000–594,000. Since April 2026, CAR-T therapy has been included in the Russian State Guarantees Programme, which makes the analysis of international economic evidence relevant. Objective: to systematize international experience in the economic evaluation of CAR-T therapy for hematological malignancies, to assess the comparability of its results, and to identify implications for the healthcare system of the Russian Federation. Material and methods. A narrative review of PubMed/MEDLINE, Scopus, Cochrane Library, eLibrary and CyberLeninka (January 2017 – June 2026) and of documents of regulatory and health technology assessment agencies was performed. For economic evaluations, country and perspective, comparator, willingness-to-pay threshold and results were compared; the Russian tariff was compared with international cost data converted at the official Bank of Russia exchange rate. A total of 50 sources were included. Results. In 47 economic evaluations, the incremental cost-effectiveness ratio (ICER) of CAR-T therapy ranged from USD 9,424 to 4,124,105 per quality-adjusted life year (QALY) in adults and from USD 20,784 to 243,177/QALY in children. The comparability of studies is limited by differences in comparators, survival extrapolation, discount rates, currencies and willingness-to-pay thresholds (from USD 37,700/QALY in China to USD 150,000/QALY in the USA). For the same indication (second-line axicabtagene ciloleucel in diffuse large B-cell lymphoma), US ICERs ranged from USD 66,381 to 142,327/QALY. A regression analysis of 45 studies found no association of cost-effectiveness with product, line of therapy or country. The Russian compulsory health insurance tariff of 7.03 million rubles (USD 88,200 at the Bank of Russia rate of April 6, 2026) is comparable with episode costs excluding the product in the UK (6.64 million rubles) and Italy (6.82 million rubles). Conclusion. Results of foreign economic evaluations of CAR-T therapy cannot be transferred to Russia without adaptation. Evidence-based reimbursement requires a national outcomes registry, data on actual costs of Russian centers with regular tariff revision, and methodological guidance for the evaluation of single-administration therapies.

FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology
Rostov State Medical University (RU), Sechenov University (RU), Krasnoyarsk State Medical University (RU), Bashkir State Medical University (RU), Ryazan State Medical University named after Academician I.P. Pavlov (RU)
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon